Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 6, 2015, Pages 947-955

  Svensson, Johanna ^a   Berg, Gertrud ^a   Wängberg, Bo ^a   Larsson, Maria ^b   Forssell Aronsson, Eva ^a,b   Bernhardt, Peter ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

177Lu DOTATATE therapy; Dosimetry; Neuroendocrine tumours; PRRT

Indexed keywords

ANTINEOPLASTIC AGENT; DOTATATE LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ARTICLE; BLOOD TOXICITY; DOSE KIDNEY FUNCTION RELATION; DOSIMETRY; DRUG ABSORPTION; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; RADIATION EXPOSURE; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR VOLUME; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; KIDNEY; KIDNEY TUBULE ABSORPTION; METABOLISM; NEUROENDOCRINE TUMORS; RADIATION RESPONSE;

AGED; BLOOD; FEMALE; HUMANS; KIDNEY; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; RADIOTHERAPY; RENAL REABSORPTION;

EID: 84943699165     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3001-1     Document Type: Article

References (34)

1. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40:78–88.
2. Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3] octreotate. J Nucl Med. 2011;52:1361–8.
3. Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging. 2005;32:1136–43.
4. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.
5. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm. 2005;20:47–51.
6. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm. 2004;19:363–70.
7. Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D′Andrea M. Dosimetry in nuclear medicine therapy: radiobiology application and results. Nucl Med Mol Imaging. 2011;55:205–21.
8. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56.
9. Gupta SK, Singla S, Bal C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm. 2012;27:593–9.
10. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.
11. Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Poppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61.
12. Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92.
13. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S103–12.
14. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.
15. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.
16. Van Binnebeek S, Baete K, Terwinghe C, Vanbilloen B, Haustermans K, Mortelmans L, et al. Significant impact of transient deterioration of renal function on dosimetry in PRRT. Ann Nucl Med. 2013;27:74–7.
17. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0),Tyr(3)-octreotate. J Nucl Med. 2005;46 Suppl 1:83S–91.
18. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–80.
19. Sward C, Bernhardt P, Ahlman H, Wangberg B, Forssell-Aronsson E, Larsson M, et al. [177Lu-DOTA0-Tyr3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg. 2010;34:1368–72.
20. Larsson M, Bernhardt P, Svensson JB, Wangberg B, Ahlman H, Forssell-Aronsson E. Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy. EJNMMI Res. 2012;2:49.
21. Fleming JS. A technique for the absolute measurement of activity using a gamma camera and computer. Phys Med Biol. 1979;24:176–80.
22. Eckerman K, Endo A. ICRP Publication 107. Nuclear decay data for dosimetric calculations. Ann ICRP. 2008;38:7–96.
23. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467–75.
24. Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.
25. He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, et al. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009;36:612–9.
26. Grubb A, Christensson A. Time for new measurements in kidney disease diagnosis and follow-up. Lakartidningen. 2013;110:1021–4.
27. Durand E, Chaumet-Riffaud P, Grenier N. Functional renal imaging: new trends in radiology and nuclear medicine. Semin Nucl Med. 2011;41:61–72.
28. Guerriero F, Ferrari ME, Botta F, Fioroni F, Grassi E, Versari A, et al. Kidney dosimetry in 177Lu and 90Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. Biomed Res Int. 2013;2013:935351.
29. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. J Nephrol. 2011;24:23–34.
30. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897–904.
31. Garske U, Sandstrom M, Johansson S, Granberg D, Lundqvist H, Lubberink M, et al. Lessons on tumour response: imaging during therapy with (177)Lu-DOTA-octreotate. A case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma. Theranostics. 2012;2:459–71.
32. Garske U, Sandstrom M, Johansson S, Sundin A, Granberg D, Eriksson B, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol. 2012;51:86–96.
33. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)] octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–46.
34. Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe(1)-Tyr(3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37:212–25. doi:10.1007/s00259-009-1216-8.